Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	16.9	22.64	46.3	42.53	12.45
Cash & Cash Equivalents	16.9	22.64	46.3	42.53	12.45
Cash Growth	-25.32%	-51.12%	8.86%	241.69%	-59.37%
Receivables	0	2.5	3.66	2.37	0
Other Current Assets	2.16	2.32	2.6	2.36	17.55
Total Current Assets	19.07	27.45	52.57	47.26	30
Property, Plant & Equipment	5.78	6.77	3.96	5.54	7.69
Long-Term Investments	0	0	0	0	7.5
Other Long-Term Assets	0	0	0.07	0.75	8.22
Total Long-Term Assets	5.78	6.77	4.03	6.28	23.41
Total Assets	24.84	34.22	56.6	53.55	53.41
Accounts Payable	3.98	3.5	3.46	5.58	6.43
Current Debt	0	2	11.67	5	19.86
Other Current Liabilities	3.24	3.21	19.63	3.96	11.95
Total Current Liabilities	7.22	8.71	34.76	14.54	38.24
Long-Term Debt	5.4	7.54	5.05	22.41	3.33
Other Long-Term Liabilities	0	0	15.58	0	0
Total Long-Term Liabilities	5.4	7.54	20.63	22.41	3.33
Total Liabilities	12.62	16.24	55.39	36.95	41.57
Total Debt	5.4	9.54	16.72	27.41	23.19
Debt Growth	-43.40%	-42.96%	-39.03%	18.21%	20.29%
Retained Earnings	-223.45	-206.04	-214.06	-185.61	-167.86
Shareholders' Equity	12.22	17.97	1.22	16.59	11.84
Net Cash / Debt	11.51	13.1	29.59	15.12	-10.74
Net Cash / Debt Growth	-12.16%	-55.73%	95.69%	-	-
Net Cash Per Share	41.38	112.96	277.71	196.20	-162.03
Working Capital	11.84	18.74	17.81	32.73	-8.24
Book Value Per Share	43.95	155.06	11.41	215.32	178.62

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).